Literature DB >> 20043295

Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.

Shuying Yang1, James Roger.   

Abstract

Pharmacokinetic (PK) data often contain concentration measurements below the quantification limit (BQL). While specific values cannot be assigned to these observations, nevertheless these observed BQL data are informative and generally known to be lower than the lower limit of quantification (LLQ). Setting BQLs as missing data violates the usual missing at random (MAR) assumption applied to the statistical methods, and therefore leads to biased or less precise parameter estimation. By definition, these data lie within the interval [0, LLQ], and can be considered as censored observations. Statistical methods that handle censored data, such as maximum likelihood and Bayesian methods, are thus useful in the modelling of such data sets. The main aim of this work was to investigate the impact of the amount of BQL observations on the bias and precision of parameter estimates in population PK models (non-linear mixed effects models in general) under maximum likelihood method as implemented in SAS and NONMEM, and a Bayesian approach using Markov chain Monte Carlo (MCMC) as applied in WinBUGS. A second aim was to compare these different methods in dealing with BQL or censored data in a practical situation. The evaluation was illustrated by simulation based on a simple PK model, where a number of data sets were simulated from a one-compartment first-order elimination PK model. Several quantification limits were applied to each of the simulated data to generate data sets with certain amounts of BQL data. The average percentage of BQL ranged from 25% to 75%. Their influence on the bias and precision of all population PK model parameters such as clearance and volume distribution under each estimation approach was explored and compared.
Copyright © 2009 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 20043295     DOI: 10.1002/pst.400

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  9 in total

1.  Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Susan Griffin; Kaye Kose; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Authors:  Thi Huyen Tram Nguyen; Emmanuelle Comets; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-11       Impact factor: 2.745

3.  Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Authors:  V M Daryani; Y T Patel; M Tagen; D C Turner; A M Carcaboso; J M Atkinson; A Gajjar; R J Gilbertson; K D Wright; C F Stewart
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-14

4.  Metabolomic Approaches to Explore Chemical Diversity of Human Breast-Milk, Formula Milk and Bovine Milk.

Authors:  Linxi Qian; Aihua Zhao; Yinan Zhang; Tianlu Chen; Steven H Zeisel; Wei Jia; Wei Cai
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

5.  Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens.

Authors:  Gellért Balázs Karvaly; Michael N Neely; Krisztián Kovács; István Vincze; Barna Vásárhelyi; Roger W Jelliffe
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

6.  Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Authors:  Wan-Yu Chu; Kim V Annink; Karel Allegaert; Alwin D R Huitema; A Laura Nijstad; Christian A Maiwald; Michael Schroth; Loubna El Bakkali; Frank van Bel; Manon J N L Benders; Mirjam M van Weissenbruch; Anja Hagen; Axel R Franz; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2021-10-07       Impact factor: 6.447

Review 7.  HCV Kinetic Models and Their Implications in Drug Development.

Authors:  Tht Nguyen; J Guedj
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-17

8.  Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.

Authors:  T H T Nguyen; J Guedj; J Yu; M Levi; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-17

9.  Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites.

Authors:  Laurent M A Favié; Timo R de Haan; Yuma A Bijleveld; Carin M A Rademaker; Toine C G Egberts; Debbie H G M Nuytemans; Ron A A Mathôt; Floris Groenendaal; Alwin D R Huitema
Journal:  Clin Pharmacol Ther       Date:  2020-06-27       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.